Check patentability & draft patents in minutes with Patsnap Eureka AI!

Bodily fluid markers of tissue hypoxia

A tissue and index technology, applied in the field of body fluid indicators of tissue hypoxia, can solve the problems of tissue hypoxia, insufficient tissue blood perfusion, etc.

Inactive Publication Date: 2009-09-23
因沃耐斯瑞士医学有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, chronically decreased cardiac output can lead to tissue hypoperfusion and relative tissue hypoxia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bodily fluid markers of tissue hypoxia
  • Bodily fluid markers of tissue hypoxia
  • Bodily fluid markers of tissue hypoxia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] research population

[0069] One hundred and twenty heart failure patients were studied, all with echocardiographically confirmed left ventricular systolic dysfunction (left ventricular (LV) ejection fraction 400IU / L. An echocardiographic study was also performed on 177 of the patients with myocardial infarction, classifying systolic function as normal, mildly dysfunctional, moderately dysfunctional, and severely dysfunctional. Age- and sex-matched normal control subjects with LV ejection fraction >50% were recruited within the local community by advertisement. All subjects submitted informed consent to participate in this study and were approved by the local ethics committee.

[0070] Endpoints in patients with myocardial infarction

[0071] Endpoints were defined as all-cause death and cardiovascular morbidity after discharge from standard hospital care (rehospitalization due to heart failure). Multivariate analyzes were performed for all endpoints except death aft...

Embodiment 2

[0129] An additional 114 patients with unstable angina or non-ST-elevating myocardial infarction (subendocardial myocardial infarction, defined as creatinine kinase levels elevated below 2 times the upper limit of normal) were studied. All patients had chest pain at rest and were admitted to hospital. Mean (range) age was 66.8 years (38-93), 74 males and 40 females. Blood samples were collected 3-5 days after admission, and the levels of troponin T (Roche Diagnostics), ORP150 protein and N-BNP were analyzed using the method described in Example 1.

[0130] Patients were followed for myocardial infarction patient endpoints as described in Example 1.

[0131] Nine deaths occurred during a mean follow-up period of 401 days (range 26-764 days). Troponin T levels were not significantly different in patients who died (0.12 (0.005-1.14) μg / L) compared to those in surviving patients (0.19 (0.005-0.557) μg / L).

[0132] In contrast, ORP150 and N-BNP levels were significantly elevated...

Embodiment 3

[0141] The impact of acute obstruction during balloon angioplasty on coronary circulation was evaluated in 19 patients with coronary artery disease who were undergoing balloon angioplasty for atherosclerosis. Plasma was collected before and 2, 6 and 12 hours after angioplasty. ORP150 levels were measured as described above. In addition, using immunoluminescence photometry in C 18 On-column measurements of levels of a cardiac marker known to indicate ventricular wall stress, type B or brain natriuretic peptide (BNP), are known to increase after other coronary occlusive events such as myocardial infarction will rise.

[0142] Figure 17 Changes in ORP150 levels in plasma after angioplasty are shown and compared to changes in BNP levels. Both indicators had significant changes over time (multiple measures ANOVA P<0.001). Furthermore, both peptide levels peaked 2 hours after angioplasty and decreased back to baseline thereafter. The peak of ORP150 level at 2 hours was signif...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The present invention provides a method for screening, diagnosing or prognosing tissue hypoxia or clinical syndromes indicative of tissue hypoxia in mammals, and a method for determining tissue hypoxia or clinical syndromes indicative of tissue hypoxia in mammals. stage or severity thereof to identify mammals at risk of developing hypoxia or clinical syndromes indicative of hypoxia, or to lactating mammals suffering from hypoxia or clinical syndromes indicative of hypoxia Methods and kits for monitoring the effect of treatment in animals following treatment. Information about tissue hypoxia or a clinical syndrome indicative of tissue hypoxia is provided by measuring the level of Oxyregulin (ORP150) or a fragment thereof in a body fluid sample of said mammal.

Description

field of invention [0001] The present invention relates to the detection and measurement of one or more indicators of tissue hypoxia or a clinical syndrome attributable to tissue hypoxia in a body fluid of a mammal. Specifically, the present invention relates to the detection of Oxyregulin (Oxygen Regulated Protein) alone or in combination with other indicators in the diagnosis and / or prognosis of tissue hypoxia or clinical syndromes attributable to tissue hypoxia in mammals. ) (ORP150) or a polypeptide fragment derived therefrom. Background of the invention [0002] Ischemic heart disease and heart failure are major health threats worldwide, yet the means to diagnose and manage these conditions are currently limited. [0003] chronic heart failure [0004] Chronic heart failure (CHF) is a common clinical syndrome that has become an increasingly important medical problem in industrialized societies with geriatric populations. [0005] Hospitalization rates for heart failu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68G01N33/577
Inventor L·额
Owner 因沃耐斯瑞士医学有限公司
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More